Cytolytic antibodies to melanocytes in vitiligo.
Patients with vitiligo have been found to have circulating antibodies to pigment cells. To evaluate the functional activity of these antibodies, a highly sensitive europium release assay was used to compare complement-mediated cytolysis of human melanocytes by sera of 56 patients with vitiligo (20 with active disease, 25 with inactive disease, 11 with unidentified disease activity) and 47 control individuals. Significant melanocyte lysis was mediated by 32 (57%) of the patients with vitiligo but by only three (6%) of the control sera (p < 0.001), and by 17 (85%) of 20 patients with active vitiligo versus 11 (44%) of 25 patients with inactive disease (p < 0.025). Mean melanocyte lysis by vitiligo sera was 24% versus 6% by control sera (p < 0.0001). A subset of 12 vitiligo sera with high titers of cytolytic antibodies to melanocytes (34% mean cytolysis) reacted minimally (< 2% mean cytolysis) to a panel of control cells that included human and murine melanomas, human fibroblasts, lung carcinoma, and rhabdomyosarcoma. These findings indicate that antibodies present in patients with vitiligo have the functional ability to selectively kill melanocytes and are more common in active disease. These observations support, but do not prove, the hypothesis that vitiligo is an autoimmune disease and that anti-pigment cell antibodies have a role in inducing the disease.
Department of Dermatology, New York University School of Medicine, New York 10016.
J
J
Cui
Y
Y
Arita
J C
JC
Bystryn
D000906:Antibodies / Q000097:blood / Q000276:immunology*; D000918:Antibody Specificity; D003602:Cytotoxicity, Immunologic; D005063:Europium / Q000378:metabolism; D006801:Humans; D008544:Melanocytes / Q000276:immunology*; D008722:Methods; D012720:Severity of Illness Index; D014820:Vitiligo / Q000097:blood / Q000276:immunology* / Q000473:pathology
D000906:Antibodies; D005063:Europium